Agoracom Blog Home

Posts Tagged ‘natural’

N.J. Bill to Lessen Jail Time For ‘Magic’ Mushrooms Moves Forward SPONSOR: Thoughtful Brands $TBI $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $SHRM.ca $RVV.ca $NOVA.ca

Posted by AGORACOM-Eric at 1:30 PM on Friday, December 11th, 2020
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564664/hub/Throught_brands_logo.png

SPONSOR: Thoughtful Brands is an established natural health products company focused in the CBD and psychedelic medicine sectors. Through their powerful eCommerce business Thoughtful is a leading direct-to-consumer provider of a wide range of natural health products throughout the United States and Europe. Click Here For More Info

Lawmakers took a step Monday to reduce penalties for possession of magic mushrooms, a criminal justice reform move that also brings them closer to passing a bill to guide the marijuana industry in New Jersey.

The Assembly Judiciary Committee voted 4-1 with one abstention to advance the bill (A5084). It does not decriminalize psilocybin, but makes possession of up to one ounce a disorderly persons offense rather than a third degree crime. That would drop penalties to a maximum of a $1,000 fine and six months in jail.

Currently, those convicted can face between three and five years in prison.

“It’s much simpler than what appears on the surface,” Assemblyman James Kennedy, D-Union, who sponsored the bill, said during Monday’s hearing. “This is really a downgrading of the charges.”

The move to legalize marijuana has been underway in New Jersey since 2014, but mushrooms only came up last month.

As lawmakers sought to pass a bill that would end arrests for up to six ounces of marijuana, Sen. Nicholas Scutari, D-Union, added a provision to downgrade penalties for psilocybin.

The measure passed the Senate by a vote of 29-4, but the Assembly did not put the amended bill for a full floor vote. The mushrooms came unexpectedly and took away from bill’s goal of ending tens of thousands of annual marijuana arrests that disproportionately involve minorities, some said.

Last week, Kennedy introduced the new bill to separate magic mushrooms. That cleared the way for conversations to resume on both the marijuana decriminalization bill and the bill that will establish rules and regulations for the legal industry.

Lawmakers came to a compromise on the setting rules for a new marijuana industry late Friday, and plan to hold a full vote on the legislation on Dec. 17. The Senate will have to repass its decriminalization bill without the mushroom provision and move on its own version.

New Jersey is not the first state to reconsider its laws on psychedelic mushrooms.

Colorado voted to decriminalize mushrooms in 2019 and Oregon voted this November to legalize their use for medicinal purposes. Several cities in California as well as Washington, D.C., have moved to end arrests over mushroom possession.

Some studies show promising medical benefits of psilocybin to treat depression and anxiety, particularly in cancer patients or others with chronic illnesses, like HIV, Mathew Johnson, a professor of psychiatry at and behavioral sciences at Johns Hopkins Medicine, said during the hearing.

He also said psilocybin carries no risk of an overdose, and the greatest risk comes from people making poor choices while impaired, or from people with certain psychological issues like schizophrenia having adverse reactions.

“When you include it even amongst a large group of legal and illegal drugs…psilocybin mushrooms always falls towards the bottom of the rankings in terms of harms to self or harms to others,” he said.

Some lawmakers remained hesitant.

“I think the bill sends the message to young people in our state that the recreational use and misuse of these substances is really not that big a deal,” said Christopher P. DePhillips, R-Bergen, who voted no on the bill.

Those in favor reiterated that the bill would not legalize or decriminalize the use of psilocybin, but would carry a punishment that more closely fit the crime.

“We open up job opportunities to so many folks who may have done this as a one-off, and then suffered with a life-long third degree indictable conviction,” said Assemblyman Raj Mukherji, D-Hudson.

“I think that public policy will be better served by treating this as a criminal act, but as a disorderly persons offense,” he said.

SOURCE https://www.nj.com/marijuana/2020/12/nj-bill-to-lessen-jail-time-for-magic-mushrooms-moves-forward.html

European Commission Reverses Course, Says CBD Should Not Be Regulated As A Narcotic SPONSOR: Thoughtful Brands $TBI $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $SHRM.ca $RVV.ca $NOVA.ca

Posted by AGORACOM-Eric at 12:28 PM on Friday, December 4th, 2020
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564664/hub/Throught_brands_logo.png

SPONSOR: Thoughtful Brands is an established natural health products company focused in the CBD and psychedelic medicine sectors. Through their powerful eCommerce business Thoughtful is a leading direct-to-consumer provider of a wide range of natural health products throughout the United States and Europe. Click Here For More Info

  • Makers of CBD foods and supplements no longer face the prospect of a blanket ban in Europe after the European Commission revised its preliminary stance that CBD should be treated as a narcotic.

The Commission sent a statement to the European Industrial Hemp Association and at least one other Novel Food authorization applicant on Wednesday that hemp-derived cannabidiol should not be regulated as a narcotic and therefore can qualify as a food.

The decision comes as a relief to Europe’s hemp industry, reassuring processors and manufacturers that their CBD edible products will not be banned from the EU market.

CBD was included in the EU’s Novel Food Catalogue in January 2019, and since then has required extensive testing and authorization from food safety authorities before it can be included in products and marketed as food across the bloc’s 27 member states.

The European Commission, the executive branch of the European Union, said in July it had stopped reviewing applications for pre-market authorization of CBD products while it decided whether CBD should be regulated as a narcotic.

The Commission cited last month’s Court of Justice ruling, which said CBD derived from the entire hemp plant is not a narcotic under an international drug treaty and is therefore subject to EU law on the free movement of goods among member states.

The Commission’s full statement to Novel Food authorization applicants reads as follows:

“In light of the comments received from applicants and of the recent Court’s judgment in case C-663/184, the Commission has reviewed its preliminary assessment and concludes that cannabidiol should not be considered as drug within the meaning of the United Nations Single Convention on Narcotic Drugs of 1961 in so far as it does not have psychotropic effect. As a consequence, cannabidiol can be qualified as food, provided that also the other conditions of Article 2 of Regulation (EC) No178/2002 are met.”

SOURCE: https://hempindustrydaily.com/breaking-european-commission-reverses-course-says-cbd-should-not-be-regulated-as-a-narcotic/

EU Top Court Rules that CBD Is Not A Narcotic Drug SPONSOR: Thoughtful Brands $TBI $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $SHRM.ca $RVV.ca $NOVA.ca

Posted by AGORACOM-Eric at 11:28 AM on Wednesday, December 2nd, 2020
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564664/hub/Throught_brands_logo.png

SPONSOR: Thoughtful Brands is an established natural health products company focused in the CBD and psychedelic medicine sectors. Through their powerful eCommerce business, Thoughtful is a leading direct-to-consumer provider of a wide range of natural health products throughout the United States and Europe

  • ‘CBD doesn’t appear to have any … harmful effect on human health,’ the judges wrote.

The European Union’s highest court ruled today that cannabidiol (CBD) isn’t a narcotic drug.

The decision by the Court of Justice of the European Union (CJEU) is a setback for EU countries that are cracking down on CBD products, arguing they are harmful to people’s health.

At issue was a French case against a Czech company that sold CBD extracted from the whole cannabis plant to use in electronic cigarette cartridges. France only allows extraction from cannabis seeds and fiber — not the whole plant.

The court ruled the law that prompted this legal action against the Czech producers was an unnecessary restriction of the free movement of goods because the substance doesn’t pose a threat to human health. 

“A decision to prohibit the marketing of CBD, which indeed constitutes the most restrictive obstacle to trade in products lawfully manufactured and marketed in other [EU] Member States, can be adopted only if that risk appears sufficiently established,” the court wrote.

First, the court set aside EU regulations on hemp — cannabis with less than 0.2 percent of the psychoactive cannabinoid tetrahydrocannabinol (THC) — in the bloc’s Common Agricultural Policy (CAP), because CBD “cannot be considered an agricultural product.”

Second, the court wrote that while countries can prohibit the free movement of goods of a banned substance like narcotic drugs, this prohibition doesn’t apply to CBD — because the substance isn’t a narcotic drug.

For example, it noted, two key U.N. conventions that classify various narcotics don’t specifically mention CBD, although they do mention “cannabis extracts.”

Banning the sale of CBD products because they’re a cannabis extract goes against the “general spirit” of the U.N. conventions, which aim to protect people’s health. CBD, unlike the psychoactive THC, “does not appear to have any psychotropic effect or any harmful effect on human health,” the court wrote.

The court conceded that a country can inhibit the free movement of goods on the basis of “public interest … provided that that legislation is appropriate … and does not go beyond what is necessary.” But such restrictions aren’t justified in this case, it said. As an example, it cited how France has not banned synthetic CBD, which has the same properties but is just not produced using the entire cannabis plant. 

The court concluded that France isn’t required to prove that CBD is dangerous like narcotic drugs, but the country’s court must look at scientific data to ensure “the real risk to public health” is not “based on purely hypothetical considerations.” 

Cannabis advocates hope that the ruling could set the groundwork for a legal CBD market. Currently, many CBD products in the EU are sold in a legal grey zone that allows cannabis to be sold for agricultural purposes.

Béchir Saket, vice president of the French cannabis advocacy group L630, said that the ruling was a “slap in the face” to France and prohibition of CBD in Europe. France in particular has fought against CBD products by shutting shops and prosecuting people who sell them.

“Many shops had been closed,” Saket said in an email. “Many managers and sometimes their families were taken into police custody or had their homes searched. [But today], the ECJ has ruled in our favour. It is a European decision that secures the CBD market.”

SOURCE: https://www.politico.eu/article/cjeu-rules-that-cbd-is-not-a-narcotic-drug/

CLIENT FEATURE: Thoughtful Brands $TBI.ca Creating CBD and Psychedelic Medicine $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $SHRM.ca $RVV.ca $NOVA.ca

Posted by AGORACOM-Eric at 7:26 PM on Tuesday, November 24th, 2020

TBI:CSE

Thoughtful Brands Inc. is an eCommerce technology company that researches, develops, markets, and distributes natural health products through various brands in North America and Europe.

  • Through continuous strategic acquisitions, the Company has a strong footprint in the CBD market, as well as the burgeoning psychedelic medicine sector.
    • Thoughtful Brands owns and operates a 110,000 square foot pharmaceutical manufacturing facility in Radebeul, Germany, where its highly skilled team conducts clinical studies utilizing naturally occurring psilocybin and other compounds found in psychedelics for the treatment of opiate addiction

2020 Key Highlights:

Signed a definitive agreement to acquire Kentucky-based American CBD Extraction Corp., a leader in quality hemp cultivation

Acquired online cannabidiol (CBD) product distributor Nature’s Exclusive from Unified Funding, LLC.:

  • Leader in online CBD sales in North America
  • US grown CBD hemp
  • Acquired at a 1.7 times revenue valuation
  • Current customer base of over 200,000 customers – with additional leads of over 600,000 potential new customers
  • Agreement finalized with Sativida OU (Estonia) and Sativida OU’s subsidiary, VIDA BCN LABS S.L to acquire Sativida in stages.

Sativida® is an online direct to consumer retailer of a vast range of organic CBD oils and cosmetics across Europe and is in the process of expanding its distribution network internationally to include the United States.

  • Award winning product line known for its minimal heavy metal content and accurate CBD levels
  • Award winning product line known for its minimal heavy metal content and accurate CBD levels
  • 100% organic products
  • Current distributor of CBD products in Spain, Portugal, Austria, Germany, France and the United Kingdom
  • One of the top search-ranked online retailer in Spain and Mexico
  • The Company acquired the intellectual property and trade names of Sativida in Spain, which will be licensed back in exchange for a royalty associated with gross revenues generated by Sativida.
  • 2019 revenue $560,000 / 64% gross margins

Thoughtful entered a Licensing and Royalty Agreement with Phenome One Corporation for the right to cultivate, harvest, process and sell a selection of cultivars from Phenome’s genetic library, and the Company was granted unlimited access to a Phenome’s proprietary nutrient intellectual property (IP) and catalogue.

Consolidated Q1 2020 gross revenue was $7.65 million, with cost of goods sold of $7.05 million, resulting in gross profits of $605,150. Operating and other operating expenses for the three months ended March 31, 2020 were $5.24 million.

Acquired Golden Path and Wild Mariposa, privately held fast-growth, direct-to-consumer eCommerce brands selling natural health products in the United States.

OPERATIONS:

UNITED STATES
  • US ecommerce, direct to consumer CBD Brand
  • 2019 Revenue of $28.7M*, EBITDA of $3.58M*
  • eCommerce technology and operations

EUROPE:

  • 110,000 sq ft, state of the art pharmaceutical manufacturing facility for research and production of natural psilocybin products
  • Award winning European eCommerce, direct to consumer CBD Brand based in Spain
  • Distribution to Spain, Portugal, France, UK and Germany

NATURES’ EXCLUSIVE

ONE OF THE LARGEST UNITED STATES-BASED ONLINE RETAILERS OF CBD PRODUCTS

Nature’s Exclusive offers a CBD hemp-oil formula intended to provide users with the therapeutic benefits that hemp may offer. The hemp oil used in the product is derived from hemp grown and cultivated in the United States.

HIGHLIGHTS

  • Leader in online CBD sales in North America
  • US grown CBD hemp
  • Acquired at a 1.7 times revenue valuation
  • Consideration of 48.2M shares priced at $0.80*
  • Current customer base of over 200,000 customers – with additional leads of over 600,000 potential new customers

A LEADING EUROPEAN BASED ONLINE RETAILER OF CBD PRODUCTS.

Sativida® is an online direct to consumer retailer of a vast range of organic CBD oils and cosmetics across Europe and is in the process of expanding its distribution network internationally to include the United States.

HIGHLIGHTS

  • Current distributor of CBD products in Spain, Portugal, Austria, Germany, France and the United Kingdom
  • One of the top search-ranked online retailer in Spain and Mexico
  • Award winning product line known for its minimal heavy metal content and accurate CBD levels
  • 100% organic products
  • 2019 revenue $560,000 / 64% gross margins

Thoughtful Brands is a client of Agoracom

Thinking Outside The Box On Psychedelics SPONSOR: Thoughtful Brands $TBI.ca $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $SHRM.ca $RVV.ca $NOVA.ca

Posted by AGORACOM-Eric at 10:53 AM on Tuesday, November 24th, 2020
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564664/hub/Throught_brands_logo.png

SPONSOR: Thoughtful Brands is an established natural health products company focused in the CBD and psychedelic medicine sectors. Through their powerful eCommerce business, Thoughtful is a leading direct-to-consumer provider of a wide range of natural health products throughout the United States and Europe

“You are driving in your car on a very stormy day.  You drive by a bus stop and see 3 people waiting there. The first is a beautiful woman, the perfect woman of your dreams.

The second is an old friend who once saved your life.

The third is a lonely old lady who looks really sick.

You have room for only one passenger.  To whom would you offer a ride?”

This was a moral and ethical dilemma actually used by Steve Jobs, co-founder of Apple, as part of a job interview.

Do you pick up the old lady because she seems to need medical attention and you should try and help her?

Do you pick up the old friend because he once saved your life and this is the perfect opportunity to repay him?

However, both those choices leave you missing out on the woman of your dreams.

The candidate hired, out of 30 applicants, however, had no trouble answering.   He simply said, “I would give the car keys to my old friend, let him drive the old lady to the hospital, and stay behind to wait for the bus with the woman of my dreams.”

His answer surprised even Jobs.

“Everyone is born with an instinct for success but only those with the ability to think outside the box succeed.”

Steve Jobs credited his outside-the-box perspective to LSD.  He felt it had made him think of the world in a different way.  He said, “Taking LSD was a profound experience, one of the most important things in my life.”  Jobs never failed to ask job applicants whether they had ever used psychedelics.

Francis Crick, of the DNA-structure discovering Watson and Crick, told numerous friends and colleagues about his LSD experimentation during the time he spent working to determine the molecular structure of DNA that houses all life’s information.
The Cambridge University’s researchers often used LSD as “a thinking tool.”  Crick actually “perceived the double-helix shape of DNA while on LSD.”

John Lennon:  “It was such a mammoth experience that it was unexplainable: It was something that had to be experienced, because you could spend the rest of your life trying to explain what it made you feel and think.”

Ken Kesey wrote “One Flew Over the Cuckoo’s Nest” in 1962. He leveraged his position as a thought leader to popularize LSD use. “I believe that with the advent of acid, we discovered a new way to think, and it has to do with piecing together new thoughts in your mind.”

Kary Mullis is a Nobel prize winning biochemist who invented the polymerase chain reaction (PCR) technique. This technique is used to make copies of DNA segments and is standard in criminal forensics, diagnosing diseases (including the current test for Coronavirus), and in genetic research. A year after winning the Nobel prize, the scientist said his LSD use in the 60’s and 70’s was far more important to his accomplishments than any courses he ever took in school. Not only that, he claims his entire legacy probably depended on using LSD. “What if I had not taken LSD ever; would I have still invented PCR?   I don’t know. I doubt it.  I seriously doubt it.”

Frances McDormand – Most people know McDormand as the plucky sheriff from the cult movie Fargo, but she “really, really enjoyed LSD.” The actress says that the drug is a deeply profound experience, and hopes that one day the government can “figure out this whole legalization thing.”

Ray Charles – LSD was most definitely on his mind. “LSD made the blind man see.”

Jean-Paul Sartre, the French existentialist philosopher, playwright, novelist, screenwriter, political activist, biographer, and literary critic, one of the leading figures in 20th century French philosophy and a key proponent of Existentialism, experimented regularly with mescaline.

Sam Harris is an American author, neuroscientist, and philosopher:
“I have two daughters who will one day take drugs. If they don’t try a psychedelic like psilocybin or LSD at least once in their adult lives, I will wonder whether they had missed one of the most important rites of passage a human being can experience.”
“There was a period in my early twenties when I found psilocybin and LSD to be indispensable tools, and some of the most important hours of my life were spent under their influence. Without them, I might never have discovered that there was an inner landscape of mind worth exploring.”
“The positive experiences were far more sublime than I could ever have imagined or than I can now faithfully recall. These chemicals disclose layers of beauty that art is powerless to capture. Positive psychedelic experiences reveal how wondrously at ease in the universe a human being can be – and for most of us, normal waking consciousness does not offer so much as a glimmer of those deeper possibilities.”

A rapidly growing number of young professionals in Silicon Valley and elsewhere insist that taking small doses of psychedelic drugs simply makes them perform better at work – becoming more creative and focused. The practice, known as “microdosing”, involves taking minute quantities of drugs such as LSD, psilocybin (magic mushrooms) or mescaline (peyote cactus).

Silicon Valley also has a long history of psychedelic drug use to boost creativity: technology stars Steve Jobs and Bill Gates both famously experimented with LSD.

At high doses, LSD powerfully alters perception, mood and a host of cognitive processes. LSD now appears to be one of the more commonly microdosed drugs. A microdose of LSD consists of about a tenth of a recreational dose (usually 10-20 micrograms), which is not potent enough to cause any hallucinations.  Instead, it is reported to heighten alertness, focus, energy and creativity.

Joe Rogan, the host of one of the most listened-to podcasts and another California resident, is a big proponent of micro-dosing mushrooms and has had numerous guests on his shows, ranging from scientists to executives to artists and writers to athletes and MMA fighters, who have shared their positive experiences from micro-dosing.

Studies have been done on the therapeutic effects of psilocybin for terminally ill cancer patients at Johns Hopkins, who were crippled by crushing, overwhelming anxiety about their impending death.

“For a few hours, I remember feeling at ease; I was simultaneously comfortable, curious and alert.  More than anything, though, I no longer felt alone.  The whole “self” thing just kind of drops out into a more timeless, more formless presence, the crushing anxiety lifted,” one patient said.

Aldous Huxley, Timothy Leary and Steve Jobs all used psychedelic drugs when they died.

In a landmark decision in August, 2020, four Canadians suffering from terminal illnesses were approved by Health Canada to receive Psilocybin therapy to treat their anxiety – marking the first time that a legal exemption has been given in Canada for patients to access psychedelic substances for treatment.

One of the four spoke to CTV News in June about his struggle with terminal cancer, and the crushing fear that such a diagnosis brings.

The 52-year-old’s anxiety about the end of his life was making his current days unbearable, and anti-anxiety medication wasn’t having the effect he needed.

It was this suffering that pushed him and three other Canadians with similar diagnoses towards Psilocybin.

Research tracking the effects of the psychedelic drug has found that it has the potential to provide long-term relief for mental health struggles such as anxiety and depression, especially in those receiving palliative care due to a terminal diagnosis.

The U.S. Center for Psychedelic and Consciousness at Johns Hopkins University in Baltimore is currently running clinical trials to assess whether the drug should be released on the market as a prescription medication.

In the 2020 US presidential elections, the state of Oregon voted in a proposition to legalize Psilocybin for mental health treatment and to decriminalize the possession of small amounts of all drugs for personal use. The new law will come into effect on 1 February 2021.   On the same day Washington, D.C. passed an initiative to decriminalize the cultivation and possession of “entheogenic plants and fungi (magic mushrooms containing psilocybin).

Kevin O’Leary, “Mr Wonderful” on the TV show Shark Tank, is backing MindMed, a neuro-pharmaceutical company testing psychedelic-inspired medicines.

O’Leary  cited the potential of its drugs to address problems like depression, alcoholism, and opioid addiction, issues that haven’t seen medical innovations in almost three decades.

Mind Medicine (MindMed) Inc. is a public company seeking to apply psychedelics to societal problems including anxiety, depression, PTSD, ADHD, cluster headaches and addiction.

The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT and an Ibogaine derivative, 18-MC. The Company has a number of trials underway, including a trial that seeks to understand whether combined dosing of MDMA and LSD could mitigate bad trips, studies into Psilocybin and studies on the use of microdoses of psychedelics for cognitive enhancement.

We are living through a seismic shift in social and legal attitudes toward….. just about everything, from gender and sexuality to mental and physical healthcare to race and class.

Now it’s time to look ahead to the next major investment trend to come out of the drug reform movement: psychedelic medicine.

Psychedelic medicine is coming back. A recent study from the Johns Hopkins University School of Medicine shows Psilocybin is an effective addiction treatment. And investors around the world are starting to take notice.

The door is slowly opening.

SOURCE: https://saultonline.com/2020/11/opinion-thinking-outside-the-box/

CLIENT FEATURE: Urban Barns (URBF: OTCQB) Takes Cubic Farming to Drought Stricken California

Posted by AGORACOM-JC at 10:15 AM on Wednesday, May 27th, 2015

What is Cubic Farming?

  • A revolution in Controlled Environment Agriculture (CEA)
  • Propriety, patent-pending, looped conveyer growing system
  • Advanced uniform LED technology
  • Automated watering and nutrients
  • Optimal conditions for crops to transition from seeds to maturity through pre-set germination, growing and harvesting phases.

Why Urban Barns Foods?

  • Unknown story due to no previous IR = best opportunity to get in
  • Tier-1 Customers = Commercial Acceptance
  • 320 square feet = 3 acres of farm production
  • $5M Market Cap = Great Risk/Reward
  • Watch this video clip to see what production looks like
  • Watch this video clip to see what the Executive Chef at Chateau Frontenac has to say

Marquee Customers Include:

Strong Institutional Ownership, 39% Owned By:

Modern Agriculture Needs Green Innovation

urbanscreen2

The Cubic Farming Advantage

  • 100% controlled environment
  • Growing 365 days a year
  • No pesticides, herbicides or fungicides
  • No GMOs
  • Minimal water requirements
  • Superior nutritional values
  • Longer shelf life
  • Consistency

Consumers Demand Clean Food

  • Globally, the BFY (BETTER FOR YOU) food category is projected to grow by 25% to over $199.8 billion in 2015.
  • GMOs, a major concern for North American consumers
  • 72% of consumers say it is important to avoid GMOs when they shop
  • 40% of consumers say they look for non-GMO claims on food
  • Natural & clean foods are increasingly mainstream
  • Not only for higher income, most educated privileged segment. It is becoming a social movement.

Urban Barns Is the Solution